Department of Chemistry, University of Sassari, Sassari (SS), Italy.
J Inorg Biochem. 2012 Mar;108:123-7. doi: 10.1016/j.jinorgbio.2011.11.007. Epub 2011 Nov 22.
Gold(III) compounds form a family of promising cytotoxic and potentially anticancer agents that are currently undergoing intense preclinical investigations. Four recently synthesized and characterized gold(III) derivatives of 2-substituted pyridines are evaluated here for their biological and pharmacological behavior. These include two cationic adducts with 2-pyridinyl-oxazolines, [Au(pyox(R))Cl(2)][PF(6)], [pyox(R)=(S)-4-benzyl-2-(pyridin-2-yl)-4,5-dihydrooxazole, I; (S)-4-iso-propyl-2-(pyridin-2-yl)-4,5-dihydrooxazole, II] and two neutral complexes [Au(N,N'OH)Cl(2)], III, and [Au(N,N',O)Cl], IV, containing the deprotonated ligand N-(1-hydroxy-3-iso-propyl-2-yl)pyridine-2-carboxamide, N,N'H,OH, resulting from ring opening of bound pyox(R) ligand of complex II by hydroxide ions. The solution behavior of these compounds was analyzed. These behave as classical prodrugs: activation of the metal center typically takes place through release of the labile chloride ligands while the rest of the molecule is not altered; alternatively, activation may occur through gold(III) reduction. All compounds react eagerly with the model protein cyt c leading to extensive protein metalation. ESI MS experiments revealed details of gold-cyt c interactions and allowed us to establish the nature of protein bound metal containing fragments. The different behavior displayed by I and II compared to III and IV is highlighted. Remarkable cytotoxic properties, against the reference human ovarian carcinoma cell lines A2780/S and A2780/R were disclosed for all tested compounds with IC(50) values ranging from 1.43 to 6.18 μM in the sensitive cell line and from 1.59 to 10.86 μM in the resistant one. The common ability of these compounds to overcome cisplatin resistance is highlighted. The obtained results are thoroughly discussed in the frame of current knowledge on cytotoxic gold compounds.
金(III)化合物形成了一类有前途的细胞毒性和潜在的抗癌药物,目前正在进行深入的临床前研究。本文评价了四种最近合成并表征的 2-取代吡啶金(III)衍生物的生物学和药理学行为。这些化合物包括两个带有 2-吡啶基噁唑啉的阳离子加合物,[Au(pyox(R))Cl(2)][PF(6)],[pyox(R)=(S)-4-苄基-2-(吡啶-2-基)-4,5-二氢噁唑,I;(S)-4-异丙基-2-(吡啶-2-基)-4,5-二氢噁唑,II]和两个中性配合物[Au(N,N'OH)Cl(2)],III 和[Au(N,N',O)Cl],IV,含有配体 N-(1-羟基-3-异丙基-2-基)吡啶-2-甲酰胺去质子化的配体 N,N'H,OH,它是由 II 中结合的 pyox(R)配体与氢氧根离子反应开环形成的。这些化合物的溶液行为进行了分析。这些化合物表现为典型的前药:金属中心的活化通常通过释放不稳定的氯配体来进行,而分子的其余部分保持不变;或者,活化可能通过金(III)还原发生。所有化合物都与模型蛋白 cyt c 迅速反应,导致广泛的蛋白金属化。ESI-MS 实验揭示了金-cyt c 相互作用的细节,并使我们能够确定结合金属的蛋白片段的性质。与 III 和 IV 相比,I 和 II 表现出不同的行为。所有测试化合物都表现出显著的细胞毒性,对参考人卵巢癌细胞系 A2780/S 和 A2780/R 的 IC(50)值在敏感细胞系中为 1.43 至 6.18 μM,在耐药细胞系中为 1.59 至 10.86 μM。突出了这些化合物共同克服顺铂耐药性的能力。在当前关于细胞毒性金化合物的知识框架内,对获得的结果进行了深入讨论。